127 related articles for article (PubMed ID: 27861596)
1. PD-L1 Status in Refractory Lymphomas.
Vranic S; Ghosh N; Kimbrough J; Bilalovic N; Bender R; Arguello D; Veloso Y; Dizdarevic A; Gatalica Z
PLoS One; 2016; 11(11):e0166266. PubMed ID: 27861596
[TBL] [Abstract][Full Text] [Related]
2. Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas.
Katsuya H; Suzumiya J; Kimura S
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001659
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.
Lin N; Song Y; Zhu J
Chin J Cancer Res; 2020 Jun; 32(3):303-318. PubMed ID: 32694896
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 immunohistochemistry assay optimization to provide more comprehensive pathological information in classic Hodgkin lymphoma.
Shi Y; Mi L; Lai Y; Zhao M; Jia L; Du T; Song Y; Li X
J Hematop; 2023 Mar; 16(1):7-16. PubMed ID: 38175373
[TBL] [Abstract][Full Text] [Related]
5. Case report: From sequence to solution: tailoring treatment for transformed follicular lymphoma (DLBCL) through next generation sequencing study.
Bouroumeau A; Perdikis-Prati S; Lang N
Front Oncol; 2024; 14():1308492. PubMed ID: 38487720
[TBL] [Abstract][Full Text] [Related]
6. Artificial intelligence-based assessment of PD-L1 expression in diffuse large B cell lymphoma.
Yan F; Da Q; Yi H; Deng S; Zhu L; Zhou M; Liu Y; Feng M; Wang J; Wang X; Zhang Y; Zhang W; Zhang X; Lin J; Zhang S; Wang C
NPJ Precis Oncol; 2024 Mar; 8(1):76. PubMed ID: 38538739
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab in the Treatment of Hodgkin Lymphoma.
Ansell SM
Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
[TBL] [Abstract][Full Text] [Related]
8. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Gibney GT; Weiner LM; Atkins MB
Lancet Oncol; 2016 Dec; 17(12):e542-e551. PubMed ID: 27924752
[TBL] [Abstract][Full Text] [Related]
10. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1
Saito R; Abe H; Kunita A; Yamashita H; Seto Y; Fukayama M
Mod Pathol; 2017 Mar; 30(3):427-439. PubMed ID: 27934877
[TBL] [Abstract][Full Text] [Related]
11. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
12. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of immune checkpoint inhibition in malignant lymphoma.
Hude I; Sasse S; Engert A; Bröckelmann PJ
Haematologica; 2017 Jan; 102(1):30-42. PubMed ID: 27884973
[TBL] [Abstract][Full Text] [Related]
14. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
[TBL] [Abstract][Full Text] [Related]
15. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY; Zhou J; Young KH
Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
[TBL] [Abstract][Full Text] [Related]
16. CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma.
Kwiecinska A; Tsesmetzis N; Ghaderi M; Kis L; Saft L; Rassidakis GZ
Br J Haematol; 2018 Mar; 180(5):744-748. PubMed ID: 27879989
[No Abstract] [Full Text] [Related]
17. Next generation predictive biomarkers for immune checkpoint inhibition.
Khagi Y; Kurzrock R; Patel SP
Cancer Metastasis Rev; 2017 Mar; 36(1):179-190. PubMed ID: 27873079
[TBL] [Abstract][Full Text] [Related]
18. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
[TBL] [Abstract][Full Text] [Related]
19. Lymphoma Heterogeneity: Three Different Histological Pictures and One Unique Clone.
Alonso-Alvarez S; Redondo-Guijo A; Blanco Ó; Alcoceba M; Balanzategui A; Caballero JC; Dávila J; González M; Caballero MD; Martín A; García-Sanz R
Case Rep Hematol; 2016; 2016():3947510. PubMed ID: 27867670
[TBL] [Abstract][Full Text] [Related]
20. Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
Musto P; Anderson KC; Attal M; Richardson PG; Badros A; Hou J; Comenzo R; Du J; Durie BGM; San Miguel J; Einsele H; Chen WM; Garderet L; Pietrantuono G; Hillengass J; Kyle RA; Moreau P; Lahuerta JJ; Landgren O; Ludwig H; Larocca A; Mahindra A; Cavo M; Mazumder A; McCarthy PL; Nouel A; Rajkumar SV; Reiman A; Riva E; Sezer O; Terpos E; Turesson I; Usmani S; Weiss BM; Palumbo A;
Ann Oncol; 2017 Feb; 28(2):228-245. PubMed ID: 27864218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
